Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?
- 11 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (20) , 1219-1222
Abstract
This editorial refers to ‘ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting’, by S. Schulz-Schüpke et al. , on page doi:10.1093/eurheartj/ehu523. ‘Well? Shall we go?’—‘Yes, let's go’. ‘They do not move.’Waiting for Godot, by Samuel Beckett, Combined treatment with aspirin and a P2Y12 inhibitor, the so-called dual antiplatelet therapy (DAPT) regimen, exerts protection against ischaemic myocardial recurrences via a double mechanism of action. First, it prevents sudden thrombotic occlusion of previously implanted stent(s) in the coronary arteries, thereby reducing the risk of stent thrombosis that occurs as a result of inflammation during healing.1,2 Since the vast majority of stent thrombosis cases are known to occur within the first weeks after stent implantation, an arbitrary 30 day to 6 weeks duration of DAPT has been investigated and a 30 day duration of therapy has become the standard of care approach after uncoated stent implantation. Secondly, DAPT has also been shown to mitigate the risk of subsequent myocardial infarction in patients not previously treated with coronary stents or arising from non-previously stented coronary segments.3,4 While the capability of DAPT to limit the progression of atherosclerosis per se has never been demonstrated, it remains likely—even if not proven—that DAPT protects the patient from the consequences of spontaneous coronary plaque rupture. The reasons why long-term prolongation of DAPT is debated, despite its unquestionable value, are two-fold. Long-term DAPT carries a time-dependent risk of major and clinically relevant bleeding complications, which affects morbidity and mortality at least as much as ischaemic recurrences.4–7 Moreover, the advent of drug-eluting stents (DES) has prompted attention …Keywords
This publication has 24 references indexed in Scilit:
- Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent ImplantationCirculation, 2014
- The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction)JACC: Cardiovascular Interventions, 2014
- A New Strategy for Discontinuation of Dual Antiplatelet TherapyJACC, 2012
- Effect of Biolimus-Eluting Stents With Biodegradable Polymer vs Bare-Metal Stents on Cardiovascular Events Among Patients With Acute Myocardial InfarctionJAMA, 2012
- Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary StentsCirculation, 2012
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarctionEuropean Heart Journal, 2012
- Drug-Eluting Stent ThrombosisJACC, 2006
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996